Skip to main content

#Influenza and Other Respiratory Viruses #Research #References (by AMEDEO, November 8 '25)

Image
By G.M.

 


    Antimicrob Agents Chemother

  1. YAO B-F, Yang Y, Xu S-S, Tang B-H, et al
    Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir.
    Antimicrob Agents Chemother. 2025 Sep 18:e0061425. doi: 10.1128/aac.00614.
    PubMed         Abstract available

  2. LODISE TP, Min J, Nathanson BH, Yucel E, et al
    Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA).
    Antimicrob Agents Chemother. 2025;69:e0056925.
    PubMed         Abstract available

  3. DE LA PORTE DES VAUX C, Veyrenche N, Silva KD, Chavarot N, et al
    Immunocompromised patients with persistent SARS-CoV-2 viral shedding >/=8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020-2024.
    Antimicrob Agents Chemother. 2025 Sep 26:e0065825. doi: 10.1128/aac.00658.
    PubMed         Abstract available


    J Virol

  4. CHANG LA, Yeung ST, Warang P, Noureddine M, et al
    Transient lung eosinophilia during breakthrough influenza infection in vaccinated mice is associated with protective and balanced Type 1/2 immune responses.
    J Virol. 2025 Nov 5:e0096525. doi: 10.1128/jvi.00965.
    PubMed         Abstract available

  5. PAGE CK, Mubassir MHM, Chopra P, Gay LC, et al
    N-glycosylation at the receptor binding site drives differences in receptor binding specificity between influenza B virus lineages.
    J Virol. 2025 Nov 5:e0103925. doi: 10.1128/jvi.01039.
    PubMed         Abstract available

  6. LIN M-W, Quintela IA, Sablani SS, Lin C-S, et al
    Recent advances in lateral flow devices and point-of-care diagnostics for highly pathogenic avian influenza A viruses.
    J Virol. 2025 Nov 4:e0148425. doi: 10.1128/jvi.01484.
    PubMed         Abstract available


    PLoS One

  7. SHARAFEDDIN SF, Chehade Z, Sayed SE, Salloum D, et al
    The effect of environmental stressors on anti-mullerian hormone levels in Lebanese women: a retrospective study.
    PLoS One. 2025;20:e0336016.
    PubMed         Abstract available

  8. BIRCH ON, Par SC, Greaves JC
    Detection and quantification of key dental pathogens through wastewater monitoring.
    PLoS One. 2025;20:e0328420.
    PubMed         Abstract available

  9. TETTEH JE, Owusu Junior P
    Co-movement between stock markets in advanced economies and Africa in times of uncertainty: A time-frequency domain approach.
    PLoS One. 2025;20:e0334325.
    PubMed         Abstract available

  10. TRAN H, Berke O, Ricker N, Poljak Z, et al
    Evaluating machine learning approaches for host prediction using H3 influenza genomic data.
    PLoS One. 2025;20:e0336142.
    PubMed         Abstract available

  11. AYOUNI I, Githaiga JN, Amponsah-Dacosta E, Kagina BM, et al
    Adapting the WHO Behavioural and Social Drivers of Vaccination (BeSD) tools and Vaccination Attitudes Examination (VAX) scale for pregnant women in South Africa: Insights from a mixed-methods pilot study.
    PLoS One. 2025;20:e0334854.
    PubMed         Abstract available

  12. JURKOWICZ M, Solomovich M, Leibovitz E, Keller N, et al
    Clinical characteristics, outcomes, and subtype diversity in hospitalized human rhinovirus (HRV) patients.
    PLoS One. 2025;20:e0335739.
    PubMed         Abstract available

  13. RHODES S, Douglas C
    Experiences of accessing primary care by those living with long Covid in New Zealand: A qualitative analysis.
    PLoS One. 2025;20:e0324489.
    PubMed         Abstract available

  14. PRENTIS J, Radhakrishnan A, Kaner E, Nandhra S, et al
    Telehealth Exercise Training in Peripheral Arterial Disease (TEXTPAD) study: A pilot randomised controlled trial in socioeconomically disadvantaged populations.
    PLoS One. 2025;20:e0327633.
    PubMed         Abstract available

  15. MILLA MN, Belanger JJ, Louis WR, Arifin HH, et al
    The 3N Model and collective support for extreme measures to combat COVID-19.
    PLoS One. 2025;20:e0335241.
    PubMed         Abstract available

  16. LORETI G, Vottero P, Olivetti EC, Vezzetti E, et al
    Delineating SARS-CoV-2 spike protein and antibodies interaction interfaces via siamese neural networks: A geometric and image-based analysis.
    PLoS One. 2025;20:e0335270.
    PubMed         Abstract available

  17. ALOSSAIMI MA, Abdel Bar FM, Elekhnawy E, ElNaggar MH, et al
    Antibacterial and antiviral potential of harmalacidine hydrochloride, a beta-carboline alkaloid, against respiratory tract pathogens: Staphylococcus aureus and H1N1 influenza virus.
    PLoS One. 2025;20:e0335014.
    PubMed         Abstract available

  18. SUN J, Wu M, Li J, Bi C, et al
    Effects of COVID-19 pandemic lockdowns on college students' physical fitness: A comparative study.
    PLoS One. 2025;20:e0335309.
    PubMed         Abstract available

  19. LORENZ E, Amuasi J, Randrianarisoa T, Rasamoelina T, et al
    Two-stage cluster sampling to assess SARS-CoV-2 seroprevalence without pre-enumeration: An example from Madagascar.
    PLoS One. 2025;20:e0334627.
    PubMed         Abstract available

  20. THACHER JD, Vilhelmsson A, Tottenborg SS, Bonde JPE, et al
    Occupational risk of COVID-19 related hospital admission in Skane, Sweden: A register-based cohort study.
    PLoS One. 2025;20:e0335662.
    PubMed         Abstract available

  21. POWELL A, Van Hout MC, Connors D, Montgomery C, et al
    A thematic analysis of flu vaccine hesitance in ethnically minoritised communities in Liverpool.
    PLoS One. 2025;20:e0333602.
    PubMed         Abstract available

  22. KONISHI K, Yamamoto S, Sada RM, Asano K, et al
    Research to evaluate safety and impact of long COVID intervention with Ensitrelvir for National Cohort (RESILIENCE Study): A protocol for a randomized, double-blind, placebo-controlled trial.
    PLoS One. 2025;20:e0335609.
    PubMed         Abstract available

  23. GONZALEZ-TORRES C, Lera L, Lizana PA
    Association between obesity and psychological distress in the Chilean population during the COVID-19 pandemic: Social Wellbeing Survey 2021.
    PLoS One. 2025;20:e0333697.
    PubMed         Abstract available

  24. LEI ZY, Zhang XM, Han JL, Xue JG, et al
    Integrating genomic epidemiology and deep mutational scanning data for prevalence forecasting of SARS-CoV-2 Omicron lineages.
    PLoS One. 2025;20:e0335520.
    PubMed         Abstract available

  25. YEETHO P, Chaiviboontham S, Sumdaengrit B
    The relationships between symptom severity post COVID-19, stress, social support and adaptation in patients with COVID-19 after discharge from the hospital.
    PLoS One. 2025;20:e0327825.
    PubMed         Abstract available

  26. MEDDAR JM, Mann D, Schwartz M, Park HG, et al
    Associations between remote patient monitoring and uncontrolled blood pressure among patients diagnosed with hypertension: Exploring variations by race/ethnicity.
    PLoS One. 2025;20:e0334887.
    PubMed         Abstract available

  27. LUO W, Wu X, Li R, Fitzpatrick M, et al
    Variant patterns and influence of inter-regional travel during the SARS-CoV-2 expansion in South Africa.
    PLoS One. 2025;20:e0329621.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  28. LI J, Wang M, Yang Y, Zhang L, et al
    Structural basis for a potent human neutralizing antibody targeting a conserved epitope on the H7 hemagglutinin head.
    Proc Natl Acad Sci U S A. 2025;122:e2503008122.
    PubMed         Abstract available

  29. HARMAND TJ, Pietrok L, Rich H, Deshycka R, et al
    A multivalent nanobody-drug conjugate to prevent and treat influenza virus infections.
    Proc Natl Acad Sci U S A. 2025;122:e2409565122.
    PubMed         Abstract available

  30. CHO E, Davis MA, Nowak JA, Izzo M, et al
    Modulating antigen processing through metal-organic frameworks to bias adaptive immunity.
    Proc Natl Acad Sci U S A. 2025;122:e2409555122.
    PubMed         Abstract available


    Vaccine

  31. BATMUNKH T, Neal EFG, Amraa O, Mazarakis N, et al
    Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.
    Vaccine. 2025;66:127840.
    PubMed         Abstract available

  32. HORA R, Ray A, Kumari A, Dutta M, et al
    Exploring the predictors for the uptake of Respiratory Syncytial Virus (RSV) vaccine under the immunization programme in India.
    Vaccine. 2025;66:127827.
    PubMed         Abstract available

  33. GE Y, Zahid A, Kuchur R, Martinez L, et al
    Using machine learning models to predict vaccine hesitancy: a showcase of COVID-19 vaccine hesitancy in rural populations during the pandemic.
    Vaccine. 2025;66:127799.
    PubMed         Abstract available

  34. NICHOLLS EJ, Onyango D, Kolodin V, Ottaway Z, et al
    The social lives of the SARS-CoV-2 vaccines: A qualitative study of vaccine understandings and decision-making among people of Black ethnicities in London, UK.
    Vaccine. 2025;66:127802.
    PubMed         Abstract available

  35. DOMINGO JL
    Differentiating COVID-19 vaccine-related adverse events from long COVID: A comprehensive review of clinical manifestations, pathophysiology, and diagnostic approaches.
    Vaccine. 2025;66:127842.
    PubMed         Abstract available

  36. DE MELO ARAUJO AC, Frugoli AG, de Sena Goncalves JE, Percio J, et al
    Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review.
    Vaccine. 2025;66:127850.
    PubMed         Abstract available

  37. YAMAGUCHI Y, Amiya S, Inokuchi S, Nagao S, et al
    Distinct trajectories of humoral immune responses after SARS-CoV-2 mRNA vaccination in autoimmune inflammatory rheumatic diseases: A group-based trajectory analysis.
    Vaccine. 2025 Oct 12:127771. doi: 10.1016/j.vaccine.2025.127771.
    PubMed         Abstract available

  38. CIMA MJ, Joshua C, Zohoori N, Porter A 3rd, et al
    Hesitancy towards routine childhood vaccinations before and after the COVID-19 pandemic in Arkansas.
    Vaccine. 2025;66:127834.
    PubMed         Abstract available

  39. SALINES M, Andraud M, Scoizec A, Schmitz A, et al
    To what extent may the duck population be protected after vaccination against highly pathogenic avian influenza? Contributions from a modelling approach and French field data.
    Vaccine. 2025;68:127905.
    PubMed         Abstract available

  40. MORRIS SE, O'Halloran A, Sundaresan D, Dawood FS, et al
    Heterogeneity in seasonal influenza vaccination opportunity and disease risk during pregnancy and in infants <6 months.
    Vaccine. 2025;68:127887.
    PubMed         Abstract available

  41. LIU D, Zhang Y, Lei J, Li J, et al
    Influenza, pneumococcal, COVID-19 vaccine willingness and uptake with influencing factors in 38,184 chinese older adults in 2022: a nationwide cross-sectional study.
    Vaccine. 2025;68:127961.
    PubMed         Abstract available

  42. SHAMSRIZI P, Eitze S, Heinemeier D, Tanzer AS, et al
    Post-pandemic questions in vaccination counseling: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines.
    Vaccine. 2025;66:127823.
    PubMed         Abstract available


    Virology

  43. MELLACE M, Ceniti C, Borrelli L, Tilocca B, et al
    Viral protein mutations enabling mammalian adaptation in Avian Influenza A viruses: Strategies for zoonotic risk mitigation and future perspectives.
    Virology. 2025;614:110731.
    PubMed         Abstract available

  44. WANG A, Hu J, Zhang Q, Zhang Y, et al
    The antiviral activity of interferon-stimulated genes (ISGs) in influenza A virus infection.
    Virology. 2025;614:110728.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »